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Aims Angiotensin II (Ang II) and tumour necrosis factor a (TNFa) are involved in the progression from
compensated hypertrophy to heart failure. Here, we test their role in the remodelling of ATP-dependent
potassium channel (KATP) in heart failure, conferring increased metabolic and diazoxide sensitivity.
Methods and results We observed increased expression of both angiotensinogen and TNFa in the failing
rat myocardium, with a regional gradient matching that of the KATP subunit Kir6.1 expression. Both
angiotensinogen and TNFa expression correlated positively with Kir6.1 and negatively with Kir6.2
expression across the post-infarction myocardium. To further identify a causal relationship, cardiomyo-
cytes isolated from normal rat hearts were exposed in vitro to Ang II or TNFa. We observed increased
Kir6.1 and SUR subunit and reduced Kir6.2 subunit mRNA expression in cardiomyocytes cultured with Ang
II or TNFa, similar to what was observed in failing hearts. In patch-clamp experiments, cardiomyocytes
cultured with Ang II or TNFa exhibited responsiveness to diazoxide, in terms of both KATP current and
action potential shortening. This was not observed in untreated cardiomyocytes and resembles the diaz-
oxide sensitivity of failing cardiomyocytes that also overexpress Kir6.1. Ang II exerted its effect through
induction of TNFa expression, because TNFa-neutralizing antibody abolished the effect of Ang II, and in
failing hearts, regional expression of angiotensinogen matched TNFa expression. Finally, Ang II and TNFa
regulated KATP subunit expression, possibly through differential expression of Forkhead box transcription
factors.
Conclusion This study identifies Ang II and TNFa as mediators of the remodelling of KATP channels in
heart failure.
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1. Introduction
ATP-dependent potassium (KATP) channels are expressed at a
high level in cardiomyocytes and play the role of metabolic
sensor.1–3 The opening of a potassium conductance in situ-
ations of low-energy supply reduces excitability of cardio-
myocytes and shortens the action potential.4 Activation of
KATP channels in the heart is central to the cardioprotection
against ischaemia afforded by preconditioning.5,6 In
addition, KATP channels were recently shown to play a key
role in physiological stress situations such as intense exer-
cise, as demonstrated by the observation that mice with
genetically reduced cardiac KATP expression only tolerate
half the level of exercise tolerated by wild-type mice.7,8
Furthermore, these mice with genetically reduced cardiac
KATP expression develop fulminant heart failure with
impaired intracellular calcium control in response to haemo-
dynamic overload.9,10 Thus, KATP channels are also required
to efficiently cope with stress in the context of an otherwise
normal energy supply.
KATP channels are heteromultimeric assemblages of
inwardly rectifying pore-forming subunits and regulatory
subunits termed sulfonyl urea receptor. There are two iso-
forms of the conductance subunit, Kir6.1 or Kir6.2, and
four isoforms of the regulatory subunits, SUR1A, SUR1B,
SUR2A or SUR2B. Importantly, the physiological as well as
the pharmacological properties of KATP channels depend on
the constitutive subunits.11,12 Kir6.1 channels have a con-
siderably lower maximal unitary conductance when com-
pared with Kir6.2 channels, but exhibit significant residual
activity at rest.13,14 Various SUR subunits confer distinct
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electrophysiological evidences indicate that sarcolemmal
KATP channels in ventricular cardiomyocytes are mostly
Kir6.2/SUR2A,15–17 immunological detection methods unam-
biguously showed Kir6.1 to be expressed as well in ventricu-
lar cardiomyocytes.18,19
We previously observed in post-infarction heart failure
marked alterations of KATP subunits expression and electro-
physiology. In short, the Kir6.1 conductance subunit and
SUR regulatory subunits were overexpressed in the infarct
border zone, conferring to failing cardiomyocytes respon-
siveness to the KATP opening drug diazoxide, which has
little effect on normal ventricular cardiomyocytes.20 An
increased Kir6.1/Kir6.2 ratio may also render sarcolemmal
KATP channels more sensitive to metabolic inhibition.
21 The
molecular and cellular mechanisms responsible for these
changes remain unknown. From the literature, overexpres-
sion of Kir6.1 has also been observed in ischaemic rat
heart,22 in which situation activation of the local renin–
angiotensin system has been implicated.23 On the other
hand, we recently showed that expression of Kir6.1 and
SUR subunits in post-infarction heart failure correlated posi-
tively with expression of the Forkhead box transcription
factors FoxO3 and FoxF2 and negatively with that of
FoxC2.24
We undertook the present study to determine whether
exposure of cardiomyocytes to angiotensin II (Ang II) could
reproduce the pattern of KATP subunits and Forkhead box
transcription factors expression observed in post-infarction
heart failure. Because the Ang II system is known to
induce expression of tumour necrosis factor a (TNFa) in car-
diomyocytes,25 we also investigated the possible involve-
ment of TNFa in the expression of KATP subunits and
Forkhead box transcription factors.
2. Methods
An expanded Methods section is provided in the Supplementary
material online.
2.1 Animal model of post-infarction heart failure
The Ethics Committee of the University of Geneva School of Medi-
cine and the Geneva State Veterinary Office approved the study pro-
tocol, which conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). We have pre-
viously described induction of post-infarction heart failure in
rats.20 In vivo gene expression data presented in this study were
obtained in samples collected in the previous study.
2.2 In vitro cultured cardiomyocytes
Adult rat cardiomyocytes were isolated and cultured as described
previously.26 The culture medium was M199 with Earle’s salts (Life
Technologies) supplemented with 20 mM creatine, 100 mM
cytosine-b-D-arabinofuranoside, and 1% FCS. Ang II (100 nM) or
recombinant rat TNFa (10 ng/mL  6  10210 M; Life Sciences)
was added at the time of plating (day 0). In some experiments, a
neutralizing anti-rat TNFa antibody (150 ng/mL; Leinco Technol-
ogies) was also included at the time of plating. Cardiomyocytes
were cultured in gelatin-coated 6 cm Petri dishes for gene
expression determinations or on laminin-coated 24 mm round glass
coverslips for patch-clamp experiments.
2.3 Gene expression analysis
mRNA expression was analysed by real-time RT–PCR according to
standard protocols as described previously.20,24 The appearance of
PCR products was monitored either by the TaqMan probe method
or by the SYBR Green method. Primers and probes for the real-time
RT–PCR are given in Supplementary material online, Table S1.
2.4 Patch-clamp analysis
Whole-cell patch-clamp recording of KATP currents and action poten-
tials were as described previously.20
2.5 Statistics
Data are presented as mean+ SEM and were compared by ANOVA
(Prism 4, GraphPad Software) followed by Bonferroni’s post hoc
test. Differences were considered significant when P was ,0.05.
3. Results
3.1 Regional expression of angiotensinogen and
TNFa in post-infarction failing hearts correlates
with Kir6 expression
Because Ang II and TNFa are two factors involved in the pro-
gression from compensated hypertrophy to heart failure, we
examined whether regional expression of these factors
would correlate with the previously described regional over-
expression of Kir6.1 and SUR2. Both angiotensinogen and
TNFa were overexpressed in post-infarction failing hearts
(Figure 1A and B), with a regional heterogeneity matching
that of Kir6.1 overexpression (Figure 1C and D). Angiotensi-
nogen and TNFa expression correlated positively with Kir6.1
expression, and TNFa expression correlated negatively with
Kir6.2 expression, across the remodelled post-infarction
myocardium (Table 1). No significant correlation was
observed between the expression of angiotensinogen or
TNFa and that of any of the SUR subunits.
3.2 Ang II and TNFa induce Kir6.1 and SUR
overexpression in cardiomyocytes
The above results prompted us to investigate whether Ang II
or TNFa could induce expression of Kir6.1 in normal cardio-
myocytes. Both Ang II and TNFa increased ANF mRNA
expression and cell size in cultured cardiomyocytes (see
Supplementary material online, Figure S1). In control cardi-
omyocytes, expression of all KATP subunits but SUR2A
remained relatively constant over the 4 days of treatment
and did not appreciably diverge from ex vivo values. Kir6.1
mRNA expression steadily increased and Kir6.2 mRNA
rapidly dropped in cardiomyocytes exposed to either Ang II
or TNFa (Figure 2). In response to Ang II, however, Kir6.2
mRNA recovered within 3 days. Similar to Kir6.1, SUR1A or
SUR1B mRNA steadily increased along the course of exposure
to Ang II or TNFa. Following an initial drop, SUR2B mRNA
increased massively by day 4. Finally, SUR2A mRNA displayed
a less consistent behaviour, with a tendency to decrease
with time that was only modestly exacerbated in response
to TNFa. Overexpression of Kir6.1 and SUR subunits in
response to TNFa were confirmed at the protein levels
(Figure 3). There was in addition a trend towards decreased
Kir6.2 expression only in response to TNFa. The protein
changes in response to Ang II were less pronounced.
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3.3 Changes in KATP currents reflect differential
KATP subunits expression
Since pharmacological properties of KATP channels depend
on the molecular channel composition,11,12 we checked
whether the changes in KATP subunit expression were
matched by changes in KATP currents (IKATP). Diazoxide
opens a subset of KATP channels normally not observed in
the sarcolemma of ventricular cardiomyocytes (Kir6.1/
SUR2B, Kir6.1/SUR1, and Kir6.2/SUR1). P1075 opens all sar-
colemmal KATP channels but the Kir6.1/SUR1 combination,
whereas glibenclamide blocks all KATP channels regardless
of the channel composition.
The basal current was larger in cardiomyocytes treated
with TNFa when compared with control or Ang II-treated car-
diomyocytes (Figure 4). P1075 increased IKATP in all the cardio-
myocytes recorded and glibenclamide completely reversed
the effect of P1075. The IKATP observed under P1075 stimu-
lation was slightly larger in cardiomyocytes treated with Ang
II or TNFa than in control cardiomyocytes. Most importantly,
diazoxide stimulated IKATP only in cardiomyocytes exposed to
either Ang II or TNFa. This effect appeared more pronounced
with Ang II. However, further analysis of theTNFa-treated car-
diomyocytes revealed that diazoxide could not evoke IKATP in all
cells exposed to TNFa. Arbitrarily splitting the TNFa-treated
cardiomyocytes into two groups according to cell size, with
the cut-off set at 140 pF (2SD above the mean of control car-
diomyocytes), showed that small cardiomyocytes (six of 15
analysed cells) were undistinguishable from control cardio-
myocytes, whereas larger cardiomyocytes (nine of 15) had
larger basal currents and their response to diazoxide was as
great as the response of cardiomyocytes treated with Ang II
(see Supplementary material online, Figure S2).
The primary physiological consequence of KATP opening in
cardiomyocytes is a shortening of the action potential.
Accordingly, we recorded action potentials in cardiomyocytes
cultured in the presence of TNFa and acutely exposed to KATP
openers (see Supplementary material online, Figure S3).
Figure 1 Regional expression of angiotensinogen and TNFa in post-infarction failing hearts correlates with Kir6 expression. (A and B) Total RNA was extracted
from cardiomyocytes obtained from the infarct border zone (IBZ), the septum (S), or the right ventricle (RV). mRNA transcript number of angiotensinogen (Agt; A)
and TNFa (B) was determined by quantitative RT–PCR in cardiomyocytes from sham (white bars, n ¼ 8) or 20 weeks post-infarction failing hearts (black bars, n ¼
11) and normalized by the number of cyclophilin transcripts. *Significantly different from sham; #significantly different from the RV in failing hearts. (C and D)
Expression of Kir6.1 and Kir6.2 (data from Isidoro Tavares et al.20) was correlated with that of Agt (C) or TNFa (D) in the various regions of 20 weeks post-
infarction failing hearts. See Table 1 for correlation parameters. Sh, pseudo-infarct border zone in sham hearts.
Table 1 Regional correlation between Kir6 and angiotensinogen
and TNFa expression in post-infarction failing hearts
Kir6.1 Kir6.2
Angiotensinogen r2 0.909 0.849
P 0.047 0.079
TNFa r2 0.941 0.943
P 0.003 0.029
Data from Figure 1 and previous study.20
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Action potential shapes and durations were similar in cul-
tured and ex vivo20 control cardiomyocytes, suggesting that
no major electrical remodelling took place during the
culture period in control conditions. In the absence of KATP
openers, triggered action potentials were longer in TNFa-
treated cardiomyocytes, possibly because of reduced Ito and
IKs expression.
27–29 Diazoxide shortened action potentials in
TNFa-treated cardiomyocytes but had no effect on control
cardiomyocytes; P1075 shortened action potentials in all
cardiomyocytes. Similar to the in vivo situation, TNFa-
treated cardiomyocytes with longer action potentials
exhibited more pronounced effects of diazoxide.
3.4 TNFa expression mediates the effects of Ang II
on expression of KATP subunits
Further analysis of the angiotensinogen and TNFa expression
patterns in post-infarction failing myocardium revealed
Figure 2 mRNA expression of KATP subunits in cardiomyocytes exposed to Ang II or TNFa. RT–PCR analysis of KATP subunits expression. Normal adult rat cardi-
omyocytes were exposed in vitro to either Ang II (100 nM; grey bars), TNFa (0.6 nM, black bars), or vehicle (white bars) for up to 4 days. Following total RNA
extraction, the mRNA transcript numbers of Kir6.1, Kir6.2, SUR1A, SUR1B, SUR2A, and SUR2B were determined by quantitative RT–PCR and normalized by
the number of cyclophilin transcripts. *Significantly different from control cardiomyocytes; n ¼ 4–8.
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a correlation between mRNA expression of these two factors
(Figure 5A). Furthermore, we confirmed the observation25
that normal cardiomyocytes exposed in vitro to Ang II
expressed more TNFa mRNA than control cardiomyocytes,
although TNFa mRNA expression tended to rise spon-
taneously in cultured cardiomyocytes (Figure 5B).
To find out whether TNFa expression was important for
the effects of Ang II, we co-incubated cardiomyocytes with
Ang II and a TNFa-neutralizing antibody. As a positive
control for the effect of the neutralizing antibody, it was
also added in combination with TNFa. Addition of the TNFa-
neutralizing antibody abolished all the effects of Ang II on
expression of KATP subunits by day 4, and blunted the
effects of TNFa (Figure 6). The TNFa-neutralizing antibody
did not change the expression of KATP subunits in control
cardiomyocytes.
3.5 Ang II and TNFa modify expression of Forkhead
transcription factors
We recently described the overexpression in the post-
infarction failing myocardium of the Forkhead transcription
factors FoxO3 and FoxF2,24 which regulate expression of
KATP subunits. Similarly, the mRNA expression of FoxO3 and
FoxF2 was markedly increased in cardiomyocytes exposed
in vitro to either Ang II or TNFa (Figure 7); again, these
overexpressions were blunted in the presence of the TNFa-
neutralizing antibody. In contrast to FoxO3 and FoxF2, two
other Forkhead transcription factors, FoxO1 and FoxC2,
were down-regulated in response to Ang II or TNFa. This
down-regulation was also dependent on TNFa, as indicated
by its relief by the TNFa-neutralizing antibody. Finally,
FoxJ2 showed an inconsistent but TNFa-dependent
regulation over the 4 days of culture (see Supplementary
material online, Figure S5; Figure 7).
4. Discussion
We had previously observed in post-infarction heart failure a
remodelling of KATP channels expression in the left ventricle
infarct border zone.20 In the present study, we demonstrate
for the first time the important role of TNFa in the regu-
lation of KATP channels expression, mediating the activation
of the local renin–angiotensin system. In vivo and in vitro
observations indicate that the Ang II–TNFa relay can
explain the remodelling of KATP channels in heart failure.
Further, we provide indirect evidence that Ang II and TNFa
regulate KATP subunits expression through alterations of
the expression of Forkhead box transcription factors.
Finally, the in vitro model used, replicating the in vivo
KATP phenotype in heart failure, is valid to study the molecu-
lar mechanisms governing KATP channels expression in heart
failure.
4.1 Ang II and TNFa as factors responsible for KATP
expression alterations in vivo
The regionalpatternofKATPexpression remodelling in thepost-
infarction failing myocardium suggests that the factor(s)
responsible for these changes had to be either locally
present or only locally active. Both the renin–angiotensin
system30 and TNFa31,32 match the first criterion. In addition,
the involvement of the renin–angiotensin system in the
overexpression of Kir6.1 in the ischaemic myocardium had
already been reported.23 Analysis of the regional expression
of angiotensinogen and TNFa in post-infarction failing hearts
revealed positive correlations with Kir6.1 expression and
Figure 3 Protein expression of KATP subunits in cardiomyocytes exposed to Ang II or TNFa. Normal adult rat cardiomyocytes were exposed in vitro to Ang II
(100 nM; grey bars), TNFa (0.6 nM, black bars), or vehicle (C; white bars) for 4 days. (A) Representative western blots for Kir6.1, Kir6.2, and SUR proteins.
The antibody used for SUR western blot analysis does not discriminate between the various SUR isoforms. (B) Semi-quantitative analysis of Kir6.1, Kir6.2, and
SUR proteins expression. *Significantly different from control cardiomyocytes; n ¼ 13–19.
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Figure 4 KATP currents (IKATP) in cardiomyocytes exposed to Ang II or TNFa. Top left panel shows the voltage ramp protocol used for recording of KATP currents.
Left: typical IKATP traces and right: mean IKATP density (current divided by cell capacitance) in cardiomyocytes exposed in vitro to Ang II, TNFa, or vehicle for 4 days.
IKATP was recorded in the absence of drug (C; circles) or in the presence of diazoxide (D; 30 mM, diamonds), P1075 (P; 100 mM, triangles), or glibenclamide (G;
1 mM, squares). *Significantly different from IKATP density measured in the absence of drug;
#significantly different from IKATP density measured in control
cardiomyocytes.
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negative correlations with Kir6.2 expression. Although cor-
relation is not a causal relationship and may arise from a
common cause, further in vitro experiments in which
exposure of normal cardiomyocytes to Ang II or TNFa
resulted in identical changes in Kir6 expression support the
conclusion that Ang II and TNFa are factors responsible for
the altered expression of Kir6 subunits in heart failure in
vivo. The participation of other locally produced or
present factors, such as tissue hypoxia33 or endothelin-1,34
cannot be excluded. Indeed, exposure of normal cardiomyo-
cytes to endothelin-1 in vitro produced similar, but less pro-
nounced, changes in Kir6 expression as Ang II or TNFa (data
not shown).
The absence of correlation between the in vivo regional
expression of angiotensinogen or TNFa and that of SUR sub-
units should not lead to the conclusion that Ang II or TNFa do
not impact on SUR expression in cardiomyocytes. In fact,
in vitro experiments show marked effects of Ang II or
TNFa on SUR mRNA and protein expression. Therefore, it
is more likely that additional, as yet unidentified, factors
also contribute to the regulation of SUR expression in vivo.
4.2 TNFa expression mediates the effects of Ang II
Observations of the present study suggest that most effects
of Ang II on expression of KATP subunits are mediated by the
paracrine or autocrine expression of TNFa. This conclusion is
indirectly supported by data showing good correlation
between the in vivo regional expression of angiotensinogen
and that of TNFa. Most conclusively, the effects of Ang II
in vitro on KATP subunits expression are essentially abrogated
in the presence of a TNFa-neutralizing antibody. That the
TNFa-neutralizing antibody less efficiently curtailed the
effects of TNFa itself is readily explained by an insufficient
titre of the antibody (150 ng/mL, i.e. 1 nM) to quell the
high concentration of TNFa used (10 ng/mL, i.e. 0.6 nM),
as the manufacturer recommends a 6:1 antibody:TNFa
stoechiometry.
However, one effect of Ang II—the reduction of Kir6.2
expression—cannot be explained by TNFa expression.
Although mostly extinct by day 4, this effect is very promi-
nent on days 1–2 (Figure 2) and is then not diminished by
the TNFa-neutralizing antibody (see Supplementary material
online, Figure S5). Therefore, Ang II directly impacts on
Kir6.2 expression independently of TNFa expression. That
this effect disappears after 3–4 days might be due to tachy-
phylaxis,35 whereas TNFa production is insufficient to
mimic the effects of 10 ng/mL exogenous TNFa.
Indirect evidence suggesting that Ang II may have
TNFa-independent effects on KATP expression and function
arises from the minor discrepancy between Kir6.1 and SUR
expression, which is highest under TNFa, and diazoxide
responsiveness, which on average is highest under Ang II.
Furthermore, a subset of cardiomyocytes exposed to TNFa
did not modify their KATP electrophysiological profile (see
Supplementary material online, Figure S3), whereas all car-
diomyocytes exposed to Ang II did. The reasons for these
differences remain unknown.
4.3 Role of Forkhead box transcription factors
A recent study from our laboratories has identified Forkhead
box transcription factors (Fox) as important regulators of
KATP subunits expression in cardiomyocytes.
24 In the setting
of post-infarction heart failure, Kir6.1 expression was posi-
tively correlated with FoxF2 and FoxO3 expression, and
negatively with FoxC2 expression, whereas Kir6.2 expression
correlated positively with FoxO1 expression. FoxF2
expression appeared to positively influence expression of
SUR subunits. Strikingly, in cardiomyocytes exposed to Ang
II or TNFa, we observed a pattern of Fox expression that
almost exactly matches the correlations from our previous
study, with the exception of FoxJ2. Therefore, it is tempting
to ascribe Kir6.1 up-regulation in the in vitro model to the
combination of FoxF2 and FoxO3 overexpression and FoxC2
repression, whereas Kir6.2 down-regulation would result
from FoxO1 repression. The causal relationship between
Fox and KATP subunits expression has been demonstrated in
neonatal cardiomyocytes and the HL-1 atrial cell line;24 it
remains to be worked out in adult ventricular myocytes.
Intriguingly, whereas FoxF2 expression correlates positively
with SUR2A and SUR2B expression in post-infarction heart
failure, overexpression of FoxF2 in HL-1 cardiomyocytes
Figure 5 Ang II induces expression of TNFa in post-infarction failing hearts
and in vitro. (A) Coexpression of TNFa and Agt in the various regions of 20
weeks post-infarction failing hearts (data from Figure 1). Correlation par-
ameters: r2 ¼ 0.87, P ¼ 0.069. IBZ, infarct border zone; S, septum; RV, right
ventricle; Sh, pseudo-infarct border zone in sham hearts. (B) Normal adult
rat cardiomyocytes were exposed in vitro to either Ang II (100 nM; grey bars)
or vehicle (white bars) for 4 days. Following total RNA extraction, the mRNA
transcript number of TNFa was determined by quantitative RT–PCR and nor-
malized by the number of cyclophilin transcripts. *Significantly different from
control cardiomyocytes; #significantly different from control at day 1; n ¼ 4.
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results in stimulation of the expression of only SUR2A. In this
study, only SUR2B expression is increased concomitantly
with that of FoxF2. Thus clearly, the relationship between
Fox transcription factors and KATP subunits expression is
complex and not univocal.
Changes in Fox expression cannot explain all changes in
KATP subunits expression. Indeed, in response to Ang II,
SUR1A increases before FoxF2 and Kir6.2 drops before
FoxO1 (Figure 2 and see Supplementary material online,
Figure S6), thus suggesting Fox-independent impacts of
Ang II on expression of these subunits. Furthermore,
despite statistical association, no FoxF2-binding site has
been identified in the promoter region of the SUR1 gene.24
The early SUR1A increase could, however, perhaps be
ascribed to transient overexpression of FoxJ2 (see Sup-
plementary material online, Figure S5), with which statisti-
cal association was observed in vivo.
4.4 In vitro replication of the KATP phenotype in
failing hearts
A remarkable finding of this study is the almost exact repli-
cation of the KATP phenotype of failing cardiomyocytes from
the infarct border zone through exposure in vitro to a single
Figure 6 Incubation with a TNFa-neutralizing antibody abolishes the effects of Ang II on the expression of KATP subunits. Normal adult rat cardiomyocytes were
exposed in vitro to Ang II (100 nM; grey bars), TNFa (10 ng/mL, black bars), or the vehicle (white bars) for 4 days in the presence or absence of a TNFa-
neutralizing antibody. Following total RNA extraction, the mRNA transcript numbers of Kir6.1, Kir6.2, SUR1A, SUR1B, SUR2A, and SUR2B were determined by
quantitative RT–PCR and normalized for the number of cyclophilin transcripts. *Significantly different from control cardiomyocytes; #significantly different
from cardiomyocytes exposed to the same agonist in the absence of the TNFa-neutralizing antibody; n ¼ 4.
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factor, either Ang II or TNFa. The replication manifests itself
through mRNA expression, protein expression, electrophysi-
ology, and pharmacology. The less pronounced changes in
protein expression in the Ang II-treated cardiomyocytes
when compared with the TNFa-treated group could be
related to a shorter exposure to a significant dose of
TNFa, as this cytokine overexpression in response to Ang II
is time-dependent (Figure 5). Interestingly, both in vivo20
and in vitro, the reduction in Kir6.2 mRNA was not
accompanied by a reduction of the Kir6.2 protein. A
similar dissociation between reduced mRNA expression and
sustained protein expression has been observed for proteins
of the fatty acid oxidation pathway in in vivo36,37 and in
vitro38,39 models of pathological myocardial hypertrophy.
The mechanisms responsible for this dissociation remain
unknown.
Figure 7 Expression of Forkhead transcription factors in cardiomyocytes exposed to Ang II or TNFa. Normal adult rat cardiomyocytes were exposed in vitro to
Ang II (100 nM; grey bars), TNFa (10 ng/mL, black bars), or the vehicle (white bars) for 4 days in the presence or absence of a TNFa-neutralizing antibody. Follow-
ing total RNA extraction, the mRNA transcript numbers of FoxO3, FoxF2, FoxC2, FoxO1, and FoxJ2 were determined by quantitative RT–PCR and normalized by
the number of cyclophilin transcripts. *Significantly different from control cardiomyocytes; #significantly different from cardiomyocytes exposed to the same
agonist in the absence of the TNFa-neutralizing antibody; n ¼ 4.
N. Isidoro Tavares et al.734
The notable deviations in the in vitro system from the in
vivo model are in the expression of SUR2A and FoxJ2.
SUR2A mRNA is unaffected by Ang II and tends to be
reduced in response to TNFa in the present study, whereas
it was uniformly increased in post-infarction myocardium
in vivo.20 This is all the more surprising as SUR2A is a
splice variant of SUR2B, which is the most markedly
increased mRNA in response to Ang II or TNFa. Thus,
despite sharing most if not all SUR2 gene regulatory
sequences, SUR2A and SUR2B splice variants exhibit
inverse responsiveness to the same agonists, possibly
through differential regulation of mRNA stability. FoxJ2 is
reduced by Ang II and to a lesser extent by TNFa in the
present study, whereas it was uniformly increased in post-
infarction myocardium in vivo.24 Intriguingly, it seems that
both TNFa-dependent and -independent signalling are
required for FoxJ2 down-regulation as it is most pronounced
in response to Ang II but prevented by co-incubation with a
TNFa-neutralizing antibody.
We could not verify whether the diverging mRNA
expression of SUR2A and SUR2B translate into reduced
SUR2A protein and increased SUR2B protein, because
isoform-specific SUR antibodies were unsatisfactory.
Western blot analysis with a pan-SUR antibody could only
indicate a global increase in SUR subunits protein expression
(Figure 3).
4.5 Molecular remodelling of sarcolemmal KATP
channels in response to Ang II and TNFa
We observed a significant up-regulation of the conductance
subunit Kir6.1 and all SUR but SUR2A subunits in cardiomyo-
cytes exposed to either Ang II or TNFa. Together with the
down-regulated Kir6.2 expression, these data suggest that
the molecular composition of the sarcolemmal KATP channels
changed to include more Kir6.1-containing complexes. Sar-
colemmal KATP channels in normal cardiomyocytes are unre-
sponsive to diazoxide,20 and so is the Kir6.2/SUR2A
assemblage when heterologously expressed.11 IKATP in Ang II-
or TNFa-treated cardiomyocytes can be stimulated by diaz-
oxide and P1075. This pharmacological profile, together
with gene expression data, is compatible with Kir6.1/
SUR2B being an important component of sarcolemmal KATP
channels in Ang II- or TNFa-treated cardiomyocytes, as
Kir6.1/SUR1 KATP channels are unresponsive to P1075.
11
Nevertheless, we cannot rule out the existence of KATP chan-
nels with heteromeric Kir6.1/Kir6.2 pores, as such hybrid
KATP channels have been shown to be responsive to diazoxide
when co-assembled with SUR2B.40
4.6 Study limitations
Several limitations of the present study need to be
discussed.
First, in the in vivo model of post-infarction, cardiomyo-
cytes were isolated from ventricular regions according to
the position of the infarct scar. In contrast, cardiomyocytes
for in vitro culture in the presence of Ang II or TNFa were
obtained indistinctly from all ventricular regions. Because
reports have demonstrated a larger density of IKATP currents
in the epicardium when compared with the endocar-
dium,41,42 single-cell data from patch-clamp experiments
could potentially be biased. Such a bias would not exist in
gene expression data, which results from the pooling of
thousands of cardiomyocytes for each condition.
Secondly, numerous observations suggest that the
expression of angiotensinogen and TNFa in the myocardium
accompanies the transition from compensated hypertrophy
to heart failure, the causal relationship remaining
unclear.43,44 This is a chronic, slowly evolving process. In
contrast, the in vitro model described herein replicates,
from a paracrine point of view, only the final stage by
abruptly exposing cardiomyocytes to high concentrations
of cytokines. To the best of our knowledge, none knows
the actual concentrations of Ang II or TNFa in the interstitial
fluid in failing myocardium. We therefore selected concen-
trations previously reported in the literature to be active
on isolated cultured cardiomyocytes.
Thirdly, KATP currents were evoked in cultured cardiomyo-
cytes by pharmacological openers, not metabolic stress, and
in clamped ATP and ADP conditions (see Supplementary
material online, Methods). Thus, potential alterations of
ATP or ADP sensitivity of the KATP channels might have
been overlooked. Indeed, reports in hypertrophied feline
cardiomyocytes have indicated a reduced sensitivity of
KATP to ATP.
45,46 In contrast, in cardiomyocytes from
TNFa-induced failing mouse hearts, the intrinsic ATP sensi-
tivity of the channels KATP was unaltered;
47 the cardiomyo-
cytes showed reduced metabolic sensitivity because of
impaired metabolic signal generation due to CK deficiency.
Finally, the evidence obtained in this study linking the
regulation of Forkhead transcription factor expression with
that of KATP subunits is only correlative. It would have
been difficult to obtain more mechanistic data, as adult
rat cardiomyocytes are not amenable to transfection, for
example, with Fox expression vectors or Fox siRNAs.
However, the data obtained concur quite substantially with
information previously obtained in the HL-1 atrial cell line.24
4.7 Conclusions
In conclusion, this study identifies Ang II and TNFa as factors
mediating the remodelling of KATP channels in the infarct
border zone, most probably through alterations of Fox
expression. The in vitro system described herein will be
very valuable in the study of the molecular mechanisms gov-
erning KATP channels expression in heart failure.
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Research online.
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